CARFLIEVA 60 MG (Carfilzomib for Injection 60 mg) is a prescription anticancer medicine used in the treatment of Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It contains Carfilzomib 60 mg, a highly effective proteasome inhibitor that helps slow the growth and spread of cancer cells by disrupting essential cellular functions required for their survival.

Multiple Myeloma develops when abnormal plasma cells multiply uncontrollably in the bone marrow, interfering with the production of healthy blood cells and causing complications such as bone damage, anemia, kidney dysfunction, and weakened immunity. CARFLIEVA 60 MG is specifically designed to target these cancerous plasma cells and support long-term disease management.

Carfilzomib works by selectively inhibiting proteasomes, which are protein complexes responsible for breaking down damaged or unnecessary proteins inside cells. Cancer cells rely heavily on proteasome activity to maintain rapid growth and survival. By blocking this process, Carfilzomib causes toxic protein accumulation within cancer cells, leading to cellular stress and ultimately triggering cancer cell death.

CARFLIEVA 60 MG is commonly prescribed for:

• Multiple Myeloma
• Relapsed Multiple Myeloma
• Refractory Multiple Myeloma
• Advanced Plasma Cell Disorders
• Combination Targeted Therapy Programs
• Hematological Malignancies
• Oncology and Hematology Treatment Protocols
• Long-Term Multiple Myeloma Management

The medicine is often used in combination with other anticancer agents such as dexamethasone, lenalidomide, or other therapies to improve treatment outcomes and enhance disease control.

Manufactured under stringent pharmaceutical quality standards, CARFLIEVA 60 MG is designed to provide consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology care.

Patients receiving Carfilzomib treatment require regular medical monitoring, including blood tests, kidney function assessments, liver function evaluations, heart health monitoring, and routine clinical examinations to ensure treatment safety and effectiveness.

Due to its targeted mechanism of action and proven clinical benefits, CARFLIEVA 60 MG has become an important treatment option in modern Multiple Myeloma management worldwide.

CARFLIEVA 60 MG (Carfilzomib for Injection 60 mg) is primarily used for the treatment and management of Multiple Myeloma and related blood cancers.

Common Uses of CARFLIEVA 60 MG

1. Multiple Myeloma

The medicine is widely used for treating patients diagnosed with Multiple Myeloma.

2. Relapsed Multiple Myeloma

CARFLIEVA may be prescribed when the disease returns after previous treatment.

3. Refractory Multiple Myeloma

The medicine may be effective in patients whose disease no longer responds adequately to certain therapies.

4. Combination Cancer Therapy

Carfilzomib is frequently administered alongside other anticancer medicines to improve treatment outcomes.

5. Plasma Cell Disorders

The medicine may be included in specialized treatment programs for plasma cell malignancies.

6. Advanced Hematology Care

CARFLIEVA supports comprehensive treatment strategies for complex blood cancers.

How CARFLIEVA 60 MG Works

Carfilzomib belongs to a class of medicines known as Proteasome Inhibitors.

CARFLIEVA works by:

• Blocking proteasome activity within cancer cells
• Preventing the breakdown of unwanted proteins
• Causing protein accumulation inside malignant cells
• Disrupting cancer cell survival pathways
• Slowing cancer cell growth and multiplication
• Promoting cancer cell death

This targeted action helps control disease progression and improve outcomes in patients with Multiple Myeloma.

Like all anticancer medicines, CARFLIEVA 60 MG may cause side effects in some patients. Side effects vary depending on treatment duration, dosage, and individual response.

Common Side Effects

1. Fatigue

Patients may experience weakness and tiredness during treatment.

2. Nausea

Mild to moderate nausea may occur after administration.

3. Vomiting

Some patients may experience episodes of vomiting.

4. Fever

Mild fever may develop during therapy.

5. Diarrhea

Digestive disturbances and loose stools may occur.

6. Shortness of Breath

Some patients may experience breathing difficulties.

7. Loss of Appetite

Reduced appetite may affect nutritional intake.

8. Anemia

Low red blood cell levels may cause weakness and fatigue.

9. Low Blood Cell Counts

The medicine may reduce:

• White blood cells
• Red blood cells
• Platelets

This may increase the risk of infections, anemia, and bleeding complications.

Serious Side Effects

Seek immediate medical attention if you experience:

• Chest pain
• Severe shortness of breath
• High fever
• Severe infection symptoms
• Severe allergic reactions
• Unusual bleeding or bruising
• Heart-related complications
• Kidney-related problems
• Severe weakness

Patients should immediately contact their healthcare provider if serious symptoms occur.

The dosage of CARFLIEVA 60 MG (Carfilzomib for Injection 60 mg) should always be determined by a qualified oncologist or hematologist.

Factors Affecting Dosage

1. Disease Condition

The stage and severity of Multiple Myeloma influence dosage planning.

2. Body Surface Area (BSA)

Dosage is commonly calculated according to body size.

3. Previous Treatment History

Prior therapies may affect treatment selection and dosing schedules.

4. Organ Function

Kidney, liver, and heart function assessments play an important role in treatment planning.

5. Treatment Response

Doctors may adjust therapy according to effectiveness and tolerability.

Important Dosage Instructions

• The injection should only be administered by trained healthcare professionals.
• Follow all prescribed treatment schedules carefully.
• Attend regular blood tests and monitoring appointments.
• Maintain adequate hydration if advised by your doctor.
• Inform your healthcare provider about any unusual symptoms.
• Do not alter treatment schedules without medical supervision.

Precautions Before Using CARFLIEVA 60 MG

Before receiving treatment, patients should inform their doctor if they have:

• Heart disease
• Kidney disease
• Liver disease
• High blood pressure
• Blood disorders
• Active infections
• Previous allergic reactions to Carfilzomib

Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.

Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.

Storage Instructions

• Store according to manufacturer recommendations.
• Protect from direct sunlight and excessive heat.
• Keep out of reach of children.
• Follow hospital and pharmacy storage guidelines.

Why Choose CARFLIEVA 60 MG?

• Trusted Carfilzomib formulation
• Advanced targeted therapy for Multiple Myeloma
• Supports modern hematology treatment protocols
• Manufactured under strict pharmaceutical quality standards
• Reliable therapeutic performance
• Suitable for relapsed and refractory Multiple Myeloma
• Helps support comprehensive cancer treatment programs

Frequently Asked Questions (FAQs)

What is CARFLIEVA 60 MG used for?

It is primarily used for the treatment of Multiple Myeloma, including relapsed and refractory disease.

What is Carfilzomib?

Carfilzomib is a proteasome inhibitor that helps destroy cancer cells by disrupting their protein recycling mechanisms.

Is CARFLIEVA 60 MG a chemotherapy medicine?

It is considered a targeted anticancer therapy commonly used in modern Multiple Myeloma treatment.

Can CARFLIEVA 60 MG be used with other anticancer medicines?

Yes, it is often administered in combination with other therapies to improve treatment effectiveness.

Does CARFLIEVA 60 MG affect blood cell counts?

Yes, the medicine may lower blood cell counts, requiring regular monitoring.

Can CARFLIEVA 60 MG affect the heart?

Some patients may experience heart-related side effects, making regular monitoring important during treatment.

Is regular monitoring necessary during treatment?

Yes, doctors typically recommend blood tests, kidney and liver function assessments, and cardiovascular monitoring throughout therapy.

Should CARFLIEVA 60 MG be administered under medical supervision?

Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, hematology, and cancer treatment.